Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

1. Dyne's Phase 1/2 ACHIEVE trial shows promising DYNE-101 efficacy for DM1. 2. Plans for global Registrational Expansion Cohort expected to support U.S. Accelerated Approval. 3. Significant splicing correction and functional improvements noted at 6.8 mg/kg dosage. 4. Safety data shows most adverse events were mild or moderate, no serious issues reported. 5. DYN stock down 35.3% to $14.91 following these updates.